Form 4: Pieris Pharmaceuticals Director Redeems Series F Preferred Stock

James A. Geraghty, a director at Pieris Pharmaceuticals, redeemed his Series F Preferred Stock for $0.01 following the effectiveness of an Authorized Share Increase.

Summary

• James A. Geraghty, a director at Pieris Pharmaceuticals, redeemed his Series F Preferred Stock.
• The redemption occurred on December 12, 2024.
• The Series F Preferred Stock was redeemed for $0.01 per share.
• The redemption was automatic and effective immediately after the effectiveness of Pieris Pharmaceuticals' Authorized Share Increase.
• The Series F Preferred Stock was originally issued to James A. Geraghty on August 7, 2024.

Sentiment

Score: 7

Explanation: The document describes a routine transaction related to the company's capital structure. It is neither particularly positive nor negative, but rather an expected event.

Industry Context

This is a standard transaction related to the company's capital structure and is not unusual for companies with preferred stock issuances.

Comparison to Industry Standards

• Redemption of preferred stock is a common practice in corporate finance, often tied to specific triggers like an authorized share increase.
• The redemption price of $0.01 is likely a nominal value, reflecting the terms of the preferred stock agreement.
• Similar transactions can be seen in other biotech companies with complex capital structures, such as those involving venture capital or private equity investments.

Stakeholder Impact

• The redemption of the Series F Preferred Stock has a minimal impact on shareholders as it is a small transaction.
• The transaction is not expected to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Series F Preferred Stock, Redemption, Director, Pieris Pharmaceuticals, Authorized Share Increase, Form 4